Compare AbCellera Biologics Inc (ABCL) vs Kraft Heinz Co (KHC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Kraft Heinz Co — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Kraft Heinz Co trades at $24.94 (market cap $30.00B). The key difference: Kraft Heinz Co is far larger — about 12.8× AbCellera Biologics Inc's market cap, and Kraft Heinz Co pays a 6.32% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KHC | |
|---|---|---|
Market Cap | $2.35B | $30.00B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $28.94 |
52-Week Low | $2.78 | $21.21 |
Enterprise Value | $1.99B | $47.04B |
Dividend Yield | — | 6.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Kraft Heinz (KHC) trades at $25.3, down 0.28% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported a net loss of $5.85 billion in 2025, driving negative profit margins, but maintains strong operating cash flow of $4.46 billion and a 6.4% dividend yield. Recent news highlights a global reorganization aimed at accelerating growth and a strategic partnership with Heineken.
KHC presents a mixed outlook: attractive valuation metrics (P/E 13.04, P/B 0.7) and bullish technicals support potential upside, but significant profitability challenges and a cautious analyst consensus (57% hold rating) indicate headwinds. Key risks include execution of the new operating structure and sustained negative earnings, while the high dividend yield offers income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
